Journal: bioRxiv

Article Title: RB1 gene mutations and their association with Endometrial Cancer

doi: 10.1101/2025.09.22.677485

Figure Lengend Snippet: (A) Lollipop graph of RB1 mutations in retinoblastoma (cBioportal). (B) Lollipop graph of RB1 mutations in different cancers (cBioportal; MSK MetTropism dataset). (C) RB1 alterations in different cancers (MSK MetTropism dataset). (D) Expression of RB1 protein across the cancers (UALCAN).

Article Snippet: Figure S3: RB1 Expressions in normal tissues (A) RB1 mRNA expression across tissues (human protein atlas). (B) RB1 protein expression across tissues (human protein atlas). (C) Protein expression of RB1 in uterine corpus endometrial carcinoma (UALCAN).

Techniques: Expressing

Journal: bioRxiv

Article Title: RB1 gene mutations and their association with Endometrial Cancer

doi: 10.1101/2025.09.22.677485

Figure Lengend Snippet: (A) Lollipop graph of RB1 mutations in endometrial cancer (cBioportal). (B) Nucleotide mutations of RB1 in endometrial cancer. (C) Types of RB1 mutations in endometrial cancer. (D) Graph for total mutation count in RB1 altered vs. unaltered endometrial cancer patients (cBioportal). (E) Graph of RB1 mutation vs. diagnosis age. (F) RB1 mutations and there occurrence in endometrial cancer.

Article Snippet: Figure S3: RB1 Expressions in normal tissues (A) RB1 mRNA expression across tissues (human protein atlas). (B) RB1 protein expression across tissues (human protein atlas). (C) Protein expression of RB1 in uterine corpus endometrial carcinoma (UALCAN).

Techniques: Mutagenesis, Biomarker Discovery

Journal: bioRxiv

Article Title: RB1 gene mutations and their association with Endometrial Cancer

doi: 10.1101/2025.09.22.677485

Figure Lengend Snippet: (A) Volcano plot of significantly mutated genes in RB1 altered vs. unaltered endometrial cancer patients (cBioportal). (B) Positions of the mutation in the chromosomes. (C) Pathway analysis of significantly mutated genes in RB1 altered vs. unaltered endometrial cancer patients (ShinyGO). (D) The other tumour suppressor genes mutational status in RB1 altered vs. unaltered endometrial cancer patients (cBioportal).

Article Snippet: Figure S3: RB1 Expressions in normal tissues (A) RB1 mRNA expression across tissues (human protein atlas). (B) RB1 protein expression across tissues (human protein atlas). (C) Protein expression of RB1 in uterine corpus endometrial carcinoma (UALCAN).

Techniques: Mutagenesis

Journal: bioRxiv

Article Title: RB1 gene mutations and their association with Endometrial Cancer

doi: 10.1101/2025.09.22.677485

Figure Lengend Snippet: (A) Volcano plot of differentially regulated genes in RB1 altered vs. unaltered endometrial cancer patients (cBioportal). (B) Pathway analysis of significantly downregulated genes in RB1 altered vs. unaltered endometrial cancer patients (ShinyGO). (C) Pathway analysis of significantly upregulated genes in RB1 altered vs. unaltered endometrial cancer patients (ShinyGO). (D) Pie chart of differentially expressed mutated genes. (C) Bar graph of upregulated genes mutated involved in different pathways.

Article Snippet: Figure S3: RB1 Expressions in normal tissues (A) RB1 mRNA expression across tissues (human protein atlas). (B) RB1 protein expression across tissues (human protein atlas). (C) Protein expression of RB1 in uterine corpus endometrial carcinoma (UALCAN).

Techniques:

Journal: bioRxiv

Article Title: RB1 gene mutations and their association with Endometrial Cancer

doi: 10.1101/2025.09.22.677485

Figure Lengend Snippet: (A) Volcano plot of differentially regulated genes in RB1 altered vs. unaltered endometrial cancer patients (cBioportal). (B) Other tumour suppressor gene’s status in RB1 altered vs. unaltered in another endometrial cancer patients (cBioportal). (C) Nucleotide mutations of RB1 in another endometrial cancer dataset. (D) Types of RB1 mutations in another endometrial cancer dataset. (E) Graph for total mutation count in RB1 altered vs. unaltered another endometrial cancer patients (cBioportal). (F) Graph of RB1 mutation vs. diagnosis age validation. (G) Lollipop graph of RB1 mutations in ovarian cancer (cBioportal). (H) Volcano plot of differentially regulated genes in RB1 altered vs. unaltered ovarian cancer patients (cBioportal). (I) The other tumour suppressor gene mutational status in RB1-altered versus unaltered ovarian cancer patients (cBioportal). (J) Lollipop graph of RB1 mutations in cervical cancer (cBioportal). (K) Volcano plot of differentially regulated genes in RB1 altered vs. unaltered cervical cancer patients (cBioportal). (L) The other tumour suppressor gene mutational status in RB1-altered versus unaltered cervical cancer patients (cBioportal).

Article Snippet: Figure S3: RB1 Expressions in normal tissues (A) RB1 mRNA expression across tissues (human protein atlas). (B) RB1 protein expression across tissues (human protein atlas). (C) Protein expression of RB1 in uterine corpus endometrial carcinoma (UALCAN).

Techniques: Mutagenesis, Biomarker Discovery

Journal: bioRxiv

Article Title: RB1 gene mutations and their association with Endometrial Cancer

doi: 10.1101/2025.09.22.677485

Figure Lengend Snippet: Due to mutations in the replication-repair machinery and viral infection (HPV), 14117 other genes were mutated, along with RB1. RB1 and E2F interaction was impaired. 5770 genes involved in cell cycle regulation, cancer-related pathways, and metabolic reprogramming were expressed differentially and regulated the endometrial cancer.

Article Snippet: Figure S3: RB1 Expressions in normal tissues (A) RB1 mRNA expression across tissues (human protein atlas). (B) RB1 protein expression across tissues (human protein atlas). (C) Protein expression of RB1 in uterine corpus endometrial carcinoma (UALCAN).

Techniques: Infection

Journal: Cell Reports Medicine

Article Title: KRAS G12D -driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC

doi: 10.1016/j.xcrm.2025.101966

Figure Lengend Snippet:

Article Snippet: In addition, the cDNA sequences of E2F1 and RING1 gene were cloned into the pRK5-HA vector. pCMV3-His-Rb (#HG10137-NH) was purchased from Sino Biological Inc. (Beijing, China). pRK5-HA-Ubi, pRK5- Ring1 , pRK5- UBE2T , deletions-mutant p53 plasmids were constructed in our previous article.

Techniques: Mutagenesis, Recombinant, Virus, CCK-8 Assay, Membrane, Concentration Assay, Modification, Transfection, Agarose Gel Electrophoresis, Plasmid Preparation, Extraction, Bicinchoninic Acid Protein Assay, Staining, RNA Extraction, H&E Stain, Viability Assay, Reporter Assay, Labeling, Western Blot, Sequencing, Control, Software

Journal: Cell Reports Medicine

Article Title: KRAS G12D -driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC

doi: 10.1016/j.xcrm.2025.101966

Figure Lengend Snippet:

Article Snippet: In addition, the cDNA sequences of E2F1 and RING1 gene were cloned into the pRK5-HA vector. pCMV3-His-Rb (#HG10137-NH) was purchased from Sino Biological Inc. (Beijing, China). pRK5-HA-Ubi, pRK5- Ring1 , pRK5- UBE2T , deletions-mutant p53 plasmids were constructed in our previous article.

Techniques: Mutagenesis, Recombinant, Virus, CCK-8 Assay, Membrane, Concentration Assay, Modification, Transfection, Agarose Gel Electrophoresis, Plasmid Preparation, Extraction, Bicinchoninic Acid Protein Assay, Staining, RNA Extraction, H&E Stain, Viability Assay, Reporter Assay, Labeling, Western Blot, Sequencing, Control, Software

Journal: Cell Reports Medicine

Article Title: KRAS G12D -driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC

doi: 10.1016/j.xcrm.2025.101966

Figure Lengend Snippet:

Article Snippet: pCMV3-His-Rb , Sino Biological , HG10137-NH.

Techniques: Mutagenesis, Recombinant, Virus, CCK-8 Assay, Membrane, Concentration Assay, Modification, Transfection, Agarose Gel Electrophoresis, Plasmid Preparation, Extraction, Bicinchoninic Acid Protein Assay, Staining, RNA Extraction, H&E Stain, Viability Assay, Reporter Assay, Labeling, Western Blot, Sequencing, Control, Software